A retrospective case series found that treatment with an interleukin (IL)-5 inhibitor reduced eosinophil levels and improved clinical outcomes in patients with drug reaction with eosinophilia and ...
GSK plc’s interleukin-5 (IL-5) portfolio got boost as depemokimab, an ultra-long-acting biologic targeting IL-5, hit its endpoints in two phase III trials in severe asthma, setting up potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results